CHANGES OF INFLAMMATORY MARKERS DURING FOLLOW-UP OF PATIENTS WITH HEART FAILURE UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
Abstract number: P-M-411
Michelucci1 A., Sofi2 F., Gori2 A., Ricciardi2 G., Pieragnoli1 P., Lenti2 M., Cesari2 F., Abdullahi Said2 A., Abbate2 R., Gensini3 G.
11Medical and Surgical C ritical Care 22Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Azienda Ospedaliero-Universitaria Careggi 33Medical and Surgical Critical Care, Thrombosis Centre, Don Carlo Gnocchi Foundation, Florence, Italy
How-to-cite Michelucci A, Sofi F, Gori A, Ricciardi G, Pieragnoli P, Lenti M, Cesari F, Abdullahi Said A, Abbate R, Gensini G. CHANGES OF INFLAMMATORY MARKERS DURING FOLLOW-UP OF PATIENTS WITH HEART FAILURE UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY. J Thromb Haemost 2007; 5 Supplement 2: P-M-411
Abstract
Introduction: Inflammation plays an important role in the progression of atherosclerosis. During the last years, several studies demonstrated that high-sensitivity C-reactive protein (hsCRP), as well as other inflammatory markers, is able to predict the development of heart failure (HF) and of other cardiovascular adverse events. However, no data exist about predictive values of inflammatory markers [hsCRP and interleukin-6 (IL-6)] in HF patients on cardiac resynchronization therapy (CRT). Aim of this study was to evaluate the interplay between inflammation and adverse events in HF patients who underwent CRT.
Methods: Before and 6 months after CRT we evaluated IL-6 and hsCRP serum levels on 140 patients with symptomatic HF (on optimized medical therapy; III-IV NYHA class) who underwent CRT.
Results: IL-6 serum levels were significantly lower (p=0.02) after 6 months of follow-up with respect to baseline [5.4 (0.07-73.07) pg/mL vs. 6.8 (0.67-65.2) pg/mL], whereas no significant difference for hsCRP levels was observed. MACE were observed in 40 patients (28.6%): 22 due to cardiac causes, and 18 due to unplanned re-hospitalization. In MACE patients no significant differences between baseline and follow-up for IL-6 and hsCRP levels, were observed [IL-6: 7.5 (0.7-53.9) pg/mL vs. 5.6 (1.3-50.1) pg/mL for baseline and follow-up, respectively (p=0.4); hsCRP: 8.2 (0.6-10.2) mg/L vs. 6.4 (1.2-145) mg/L for baseline and follow-up, respectively (p=0.4)]. However, in patients who not occurred MACE at follow-up, a significant decrease for both parameters was observed [IL-6: 6.8 (1.2-56.1) pg/mL vs. 4.7 (0.1-73.1) pg/mL for baseline and follow-up, respectively (p=0.01); hsCRP: 5.3 (0.1-21.8) mg/L vs. 2.9 (0.2-34.8) mg/L for baseline and follow-up, respectively (p=0.001)].
Conclusions: The significant decrease of inflammatory markers observed in patients who not occurred MACE at folllow-up, indicate a relationship between inflammation and occurrence of adverse events in HF patients who underwent CRT.
